DDInter1042 DDInter1055
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
Levofloxacin {u} (Compound) upregulates {v} (Gene) CPVL
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Levofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dysphagia
Levofloxacin (Compound) resembles Enoxacin (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene)
Levofloxacin (Compound) upregulates CPVL (Gene)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Levofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Levofloxacin (Compound) downregulates TRIB3 (Gene)
Levofloxacin (Compound) causes Dysphagia (Side Effect)